Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay
European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.
You may also be interested in...
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.